Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: A phase II study

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 3, 2005, Pages 271-276

  Schena, M ^a   Barone, C ^a   Birocco, N ^a   Dongiovanni, D ^a   Numico, G ^b   Colantonio, I ^b   Bertetto, O ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Head and neck cancer; Palliative chemotherapy; Phase II; Toxicity; Weekly chemotherapy

Indexed keywords

CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FLUOROURACIL; ONDANSETRON; PACLITAXEL; RANITIDINE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CARCINOMA; HUMAN; INFECTION; KIDNEY DISEASE; MALE; METASTASIS; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PACLITAXEL; VOMITING;

EID: 12444313925     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0875-1     Document Type: Article

References (30)

1. Boring CG, Squires TS, Tong T (1992) Cancer statistics 1992. CA Cancer J Clin 42:19-38
2. Zbaren P, Lehmann W (1987) Frequency and sites of distant metastases in head and neck squamous-cell carcinoma. Arch Otolaryngol Head Neck Surg 113:762-764
3. Vokes EE, Weichselbaum RR, Lippman S, et al (1993) Head and neck cancer. N Engl J Med 328:184-194
4. Morton RP, Rugman F, Dorman EB, et al (1985) Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 15(3):283-289
5. Forastiere AA, Metch B, Schuller DE, et al (1992) Randomized comparison of cisplatin plus 5-fluorouracil versus carboplatin plus 5FU versus methotrexate in advanced squamous cell carcinoma of the head and neck. Clin Oncol 10(8):1245-1251
6. Pinto HA, Jacobs C (1991) Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin North Am 5:667-686
7. Forastiere AA (1993) Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. Semin Oncol 20 [Suppl 3]:56-60
8. Shin DM, Glisson BS, Khuri FR, Ginsberg L, Lawhorn K, Hong WSM (1997) Recent advances in paclitaxel containing chemotherapy for metastatic squamous cell carcinoma of the head and neck. Semin Oncol 24(6 suppl 19):S19-33-S19-37
9. Forastiere AA, Shank D, Neuberg D, et al (1998) Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82(11):2270-2274
10. Hitt R, Hornedo I, Colomer R, et al (1997) Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer. Semin Oncol 24(1 Suppl 2):S2-8-S2-64
11. Forastiere AA, Leong T, Rowinsky E, et al (2001) Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: an Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19(4):1088-1095
12. Benasso M, Numico G, Rosso R, et al (1997) Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose finding study. Semin Oncol 24(6 suppl 19):S19-46-S19-50
13. Hussain M, Gadgeel S, Kucuk O, et al (1999) Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 86(11):2364-2369
14. Shin DM, Glisson BS, Khuri FR, et al (1998) Role of paclitaxel, ifosfamide and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 25(2 Suppl 4):40-44
15. Patel K, Anthney DA, Crellin AM, Sebag-Montefiore D, Messruther J, Seymour MT (2004) Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Ann Oncol 15:568-573
16. Fizazi K, Zelek L (2000) Is 'one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasm. Ann Oncol 11:133-149
17. Kish JA, Ensley JF, Jacobs J, et al (1985) A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56(12):2740-2744
18. Weiner LM, Colarusso P, Goldberg M, et al (1997) Combined-modality therapy for esophageal cancer: a phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. Semin Oncol 24(6 suppl 19):S19-93-S10-95
19. Goldberg M, Farma J, Lampert C, et al (2003) Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5 fluorouracil and radiation in resectable esophageal carcinoma: a phase I report. J Thorac Cardiovasc Surg 126(4):1168-1173
20. Miller AB, Hoogstraten B, Staquet M, et al (1981) Reporting results of cancer treatment. Cancer 47:207-214
21. Van Oosterom A (1992) Tumor eligibility and response criteria for phase II and III studies and (sub)acute toxicity grading with suggested amendments to WHO criteria. EORTC Data Center Producers Manual, 2nd edn. EORTC, pp 119-133
22. Simon R (1989) Optimal two-stage design for phase II clinical trials. Control Clin Trials 10:1-10
23. Degardin M, Oliveira J, Geoffrois L, et al (1998) An EORTCECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 9:1103-1107
24. Catimel G, Vermorken JB, Clavel M, et al (1994) A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5(6):543-547
25. Koussis H, Chiarion-Sileni V, Scola A, et al (2000) Carboplatin plus vinorelbine in head and neck or oesophageal carcinoma in the elderly or in patients with poor performance status (PS): preliminary report. Ann Oncol 11 [Suppl 4]:94
26. Fountzilas G, Stathopoulos G, Nicolaides C, et al (1999) Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 10(4):475-478
27. Hitt R, Castellano D, Hidalgo M, et al (1998) Phase II trial of cisplatin and gemcitabine in advanced squamous cell carcinoma of the head and neck. Ann Oncol 9(12):1347-1349
28. Espinosa E, Zamora P, Milla A, et al (2002) A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 24(12):1054-1059
29. Haddad RI, Van Echo DA (2003) Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. Cancer Chemother Pharmacol 52(4):303-306
30. Murphy B, Li Y, Cella D, et al (2001) Phase III study comparing cisplatin (C) & 5-Fluorouracil (F) versus cisplatin & paclitaxel (T) in metastatic/recurrent head & neck cancer (MHNC). Proceedings of ASCO No. 894